Langerhans cell histiocytosis (LCH) is related diseases characterized by proliferation of Langerhans cell with involvement of bone, skin, lung and other organs. LCH usually occurs in childhood and are presented as multiple small papules or eczematoid lesion mostly. We report a 50-year-old man with 3 brown lichenoid patches on left dorsal foot. He was diagnosed pulmonary LCH 5 years ago. Typical LC cells on skin lesion and CD1 complex positive staining confirm the diagnosis of LCH. We consider brown lichenoid patches may be a previously unreported cutaneous presentation in cutaneous or multisystem LCH. 
INTRODUCTION
Langerhans cell histiocytosis (LCH) is a rare, clinically polymorphous group of disorders all having in common proliferation of Langerhans cells. The recognized clinical variants of LCH include Letterer-Siwe disease, HandSchuller-Christian disease, eosinophilic granuloma, and congenital self-healing reticulohistiocytosis 1 . We report a 50-year-old man with brown lichenoid patches, unusual cutaneous presentation of LCH, on left dorsal foot.
CASE REPORT
A 50-year-old man attended Department of Dermatology with a 2 year duration of brown-colored patches on the left dorsal foot. Lobular consolidation was shown on chest X-ray in health screening 5 years ago, but he had no symptoms. He was diagnosed pulmonary LCH by chest CT and percutaneous transthoracic needle aspiration. He is a heavy smoker and has 45 pack-years smoking history. On physical examination, there were three brown lichenoid patches on left dorsal foot (Fig. 1 3A, B). Immunochemistry for CD 1a complex and S-100 protein showed positive staining but CD 68 show negative ( Fig. 3C, D) . The patient did not receive treatment but he visited our Department of Pulmonary Medicine regularly.
To his last visit (1 year later) we can't find any changes on pulmonary and cutaneous lesions.
DISCUSSION
LCH encompasses a group of disorders of unknown origin with widely diverse clinical presentations and outcomes, characterized by infiltration of the involved tissues by large numbers of LC. LCH is characterized clinically by various combinations of systemic and cutaneous manifestations. LCH consists of Letterer-Siwe disease, HandSchuller-Christian disease, eosinophilic granuloma, and congenital self-healing reticulohistiocytosis 1 .
The definite diagnosis of LCH should fit light microscopy Sang et al. 4 Jung et al. 5 Chang et al. 6 Kim et al. 7 Lee et al. Modi et al. 12 Johno et al. 13 Mejia et al. 14 Aoki et al. 15 Jain et al. 16 Lee et al. 17 Holme et al. 18 Gonul et al. 19 Skin (Table 1) 4-8 . Although LCH is commonly thought to be confined to children, a small percentage of patients are elderly and may have cutaneous involvement for many years before the onset of visceral disease 9 . Adult LCH has difference with childhood LCH in organ involvement. Bone disease is most common in childhood LCH, but pulmonary disease is very frequent in adult LCH. Skin disease and diabetes insipidus are frequent in both type 10 .
Cutaneous manifestations are common in multi-organ involved LCH and adult LCH skin lesions are similar that of childhood. The typical lesion is yellowish or reddish small multiple papules with ulceration, crusting or a hemorrhagic change on the trunk and scalp. Especially the scalp lesions resemble seborrheic dermatitis and other common finding is an eczematous lesion on intertriginous area 11 .
On the other hand, unusual cutaneous manifestations of LCH such as varicelliform eruption, solitary nodule and nail fold swelling are also reported (Table 2 ) [12] [13] [14] [15] [16] [17] [18] [19] . In this case, cutaneous lesions are shown as brown lichenoid patches on left dorsal foot and we consider this is rare in LCH patients. Surgery, steroid cream, topical nitrogen mustard, interferon IL, PUVA, isotretinoin, thalidomide can be treatment for skin manifestations of LCH. Single system-patients should receive prednisone and vinblastine for 6 wk followed by continuation treatment with 6-mercaptopurine, prednisone, and vinblastine for 6 months. Patients with multisystem disease should receive prednisone and vinblastine for 6 wk followed by continuation treatment with 6-mercaptopurine, prednisone, and vinblastine for 6 or 12 months, respectively 20 .
LCH presents a very wide clinical spectrum and variable course. Prognostic factors are including age of patients at diagnosis, numbers of organ involved and organ dysfunction. Single system disease is usually associated with a good prognosis, but multisystem disease may be fatal 11 .
